FRS3 and lung carcinoma: We discovered several SL pairs that have been previously reported in the literature, such as BRAF-MAP2K1 in CRC (Salama et al, 2020; Klute et al, 2022), KRAS-GRAP2 in lung cancer (Luo et al, 2009), and MYC-UBE2O in breast cancer (Kessler et al, 2012) and novel putative SL pairs, such as TP53-FRS3 in blood cancer and CCND1-METTL1 in liver cancer from CRISPR analysis.